reason report
bottom line publish individu one-pag compani
preview cardio ew nvcn
large-cap diversifi diabetes/oth
pre-announce earn mani
pre-announce sever yet provid guidanc
top pick necessarili specif remain
large-cap mid-cap small-cap given
prefer revenu growth acceler margin expans
strong product cycl upward estim revis potenti
see opportun smid-cap amongst
compani pre-announce see signific
room upsid -- notabl expect
anoth strong top-lin beat us y/i street
base just-announc sale rep number exit
rep vs exit believ domest
busi alon could deliv upsid quarter share
nearli high think risk/reward
profil favor head result particularli given
high level convict behind potenti beat also
expect meaning upsid current estim y/
street driven ramp maci adopt trend
compani continu train surgeon util
new exist center continu ramp despit face tough
comp model current assum exit train
surgeon includ new surgeon train quarter vs
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
januari edt rx trend deriv im health
train util procedur per surgeon vs
estim us leav plenti room upsid
remain top smid-cap pick year
believ magnitud beat may bit mute
drive meaning bounc share rather see meaning
upsid come rapidli expand access instal
base/revenu growth acceler come alreadi
pre-announce guid converg fulli enrol
believ share trade quarterli result move
year well data like releas sometim late
svb leerink estim factset
quarter expect pre-announce sale y/i ahead
us street y/i time pre-announce
continu compani growth momentum mark consecut quarter
y/i revenu growth believ driven cardiogen shock high-risk pci
util manag also rais sale guidanc
impli revenu growth y/i notabl midpoint well ahead
quarterli beat expect manag come line current om
assumpt reiter oper margin guidanc compani
continu drive oper leverag well invest clinic trial pre-announce
beat prompt us rais sale estim
vs previous given pre-announce lack
controversi like around quarter expect increment commentari call
center around stemi trial potenti trial size trial design time well
potenti new indic could impact long-term growth trajectori pt vs
stanc believ well track exceed goal revenu
now-high sale estim nearli given recent pullback share --
high view attract entri point investor look
top-tier sale growth margin profil stori signific runway sustain
quarter expect abl deliv modest sale ep beat despit currenc
headwind like ramp wed expect meaning out-performance across key product line vs us
consensu notabl diabet diagnost diabet believ deliv beat
above-consensu estim diabet sale beat street
estim ep believ lever pull drive least penni beat vs street
y/i report sale estim slightli consensu reflect
organ sale growth ex fx manag provid guidanc earn call
januari expect guid organ sale growth rang bracket
consensu ep rang impli ep growth y/i current ep
estim call also expect address key question around growth china
sale given on-going trade disput prompt neg pre-announce tax
rate trend beyond anoth major multi-national competitor point below-trend ep
growth due rise tax sustain above-market sale growth back key
recent product launch like libr alin well like mitraclip indic expans
stanc us much execut stori compani drive new product cycl
medic devic busi steadi turnaround nutrit busi deliv
oper leverag comp get increasingli tougher remain sidelin given
uncertainti around abil drive sustain above-market sale growth posit oper
leverag recent success new product launch anniversari
resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop ep region total segment total cardiovascular establish diabet compani report svb leerink estim factset visibl resultsactuallp estimate y/i consensusvariancetot good gross gener administr develop ep metricstot impella custom patient treat per breakdownu impella impella impella non-impella compani report factset consensu visibl alpha consensu svb leerink inc outperform price
quarter expect pre-announce sale y/i ahead us
y/i street time pre-announce sale come
y/i ou sale constant currenc basi declin report
believ like saw better momentum build across atriclip busi also open
busi guid full-year sale y/i vs now-high estim
consensu compani continu expect ebitda profit
adjust ebitda loss come within previous guid given pre-announce
expect commentari call focu level conservat bake guidanc time
converg data bogey trial must hit drive adopt post-approv
approv could chang long-term growth outlook
stanc believ sustain double-digit sale growth compani near term still-
signific runway growth open clip busi adopt momentum continu build
longer term believ mi drive sale growth inflect converg come on-line
time-frame inclin think multibillion-dollar market opportun underappreci street
minim valu assign current valuat level relat specif believ
like deliv upsid current sale guidanc upcom
converg data repres major posit catalyst share
quarter expect deliv larg in-lin sale quarter solid ep beat believ
possibl vs us consensu guidanc larg predic stronger
gross oper margin regard guidanc believ manag exercis prudent
conservat reset bar better posit consist beat rais
like guid top-lin growth low-to mid-single-digit rang oper ep
midpoint prompt us lower sale ep estim ahead
print guid now-low sale ep estim
previous line consensu reflect conservat around
medic deliveri tax rate well headwind brevibloc competit fx
margin relat key controversi call wed expect focu turnaround
medic deliveri success return full suppli regain market share
busi dynam chang capit deploy like asset price come
recent month
stanc take conserv stanc sale growth inclin
think deliv upsid now-low estim consensu ultim believ
product innov stori near long term given compani track record solid
execut post-split specif outperform first quarter believ
issu impact medic deliveri clinic nutrit transient look longer
term continu believ bax long-term guidanc sale compound-annual-growth-rate
oper margin ramp still achiev compani like
supplement growth profil next year
resultsactuallp estimate y/i growthconsensusvariancetot product gener administr develop incom ep region breakdownopen-heart ablat ablat tool compani report factset consensu visibl alpha consensu svb leerink resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop ep region total baxter baxter product renal therapi deliveri surgeri baxter compani report factset consensu visibl alpha consensu svb leerink boston scientif corpor outperform price
quarter expect pre-announce sale y/i report
y/i oper y/i organ line estim y/i report
street time pre-announce bsx solid result organ sale growth
despit face tougher comp broad-bas look believ manag like
guid oper top-lin growth someth around rang organ like
within manag oper sale growth compound-annual-growth-rate guidanc time-frame
view leav ampl room upsid upcom new product launch lotu
relaunch europ launch btg sale synergi expect close
street report sale estim y/i report
respect manag like bracket consensu rang
perhap issu guidanc given pre-announce think focu
earn call driver sale growth acceler impact new product
launch capit deploy access adjust free cash flow
stanc believ repres one strongest reliabl top- bottom-lin
growth acceler stori large-cap med-tech view share like outperform
med-tech and/or broad-bas healthcar sell-off also believ repres one best
product portfolio/pipelin stori continu adopt momentum watchman acur
wavewrit on-going roll-out eluvia crt-p lotu eu relaunch
launch overal expect deliv sustain high-single-digit sale growth
exceed goal oper margin reiter op pt
quarter expect pre-announce revenu y/i ahead us
consensu y/i respect overal stack comp growth
acceler bp quarter could speak benefit increment revenu stream
come orbusneich intern encouragingli compani note core growth also
increas low double-digit quarter narrow guidanc rang
y/i may disappoint investor given midpoint rang
unchang despit quarterli beat given pre-announce think focu call
like fall busi growth driver go-forward outlook potenti conservat
reflect updat guidanc
stanc continu believ repres sustain double-digit growth stori
improv execut given believ compani signific competit advantag
calcifi below-the-kne lesion within peripher well grow market-lead posit
highli under-penetrated coronari market execut improv new revenu stream
orbusneich intern kick believ well-posit growth acceler
resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop incom ep region total product total compani report factset consensu visibl alpha consensu svb leerink resultsactuallp estimate y/i growthconsensusvariancetot product gener administr develop incom ep metricspad new new pad devic cad devic breakdownpad devic devic product compani report factset consensu visibl alpha consensu svb leerink dexcom inc outperform price
quarter expect pre-announce revenu least y/i well
ahead us consensu y/i robust growth particularli
encourag broad-bas driven domest despit like on-going price headwind
ramp competit intern sale intern sale
also issu guidanc total revenu expect rang
us clearli reflect prudent conservat like beatabl lower
sale number high end manag just-issu
guidanc rang reflect even dramat price headwind captur believ bear-
case scenario model sensor price per day vs exit
compar believ lower-cost competit product stand per day given
pre-announce think focu call center put take
guidanc conserv may impli price pressur commerci patient
pharmaci vs dme new patient add europ light ramp competit
commentari around sensor featur margin profil go-to market strategi least
could hear around next-gen sensor potenti timing/ext impact
increment revenu stream new market gestat diabet in-hospit type
stanc view long-term guidanc conserv like beatabl
factor believ base-cas -- even borderlin bear-cas -- scenario price
new patient add perspect strong result need deliv less
compound-annual-growth-rate reach long-term sale target leav ampl room
upsid ultim believ consensu estim beyond move meaning higher
quarter expect ew deliv basic in-lin quarter vs estim
y/i consensu thv transcathet heart valv busi
estim y/i q/q vs street quarterli tavr survey
suggest sequenti declin vs mid-to-high singl digit sequenti growth believ street
model inclin think ew deliv best in-lin thv quarter particularli given recent
eu share loss like continu given ultra start target roll-out
centera first full quarter given drive share reaction believ ew
share could sell print though acknowledg investor want upcom low risk
data march analyst day ew guid sale ep guidanc
tavr sale growth guidanc manag like maintain
stanc continu believ ew retain market-lead posit massiv
market opportun near-to-medium term ramp intermedi eventu low-risk could
progress slowli saw high-risk/ inoper rel elev street expect
still premium valuat level sens ew continu deliv strong beat
rais quarter order drive share upsid sens out-performance
gotten increasingli tougher come
resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop continu ep region domest product tavr corevalv tavr tavr transcathet aortic valv surgic heart valv critic transcathet mitral tricuspid ew compani report svb leerink estim factset visibl resultsactuallp estimate y/i growthconsensusvariancetot good gross gener administr develop ep region total breakdown total sensor transmitt compani report factset consensu visibl alpha consensu svb leerink inc outperform price
quarter expect deliv anoth strong top-lin beat us
y/i street base just-announc sale rep number exit
rep vs exit believ domest busi alon could deliv
upsid quarter also believ rep number combin compani target
reach employe new cleveland facil end repres direct
sale rep would impli anoth add least set anoth year
out-performance still wed expect manag reiter current sale guidanc
slowdown howev concern mount around fundament
shift either market size estim and/or adopt ramp competit product
offici launch rmd mobi manag like remain conserv
outlook still continu believ poc adopt ramp acceler next
quarter even year ultim reach penetr leav room signific near
long-term upsid
stanc view best-in-class portable-oxygen-concentr poc uniqu
dtc busi model posit compani sustain double-digit growth trajectori longer
term remain confid midst poc adopt inflect
maintain signific competit advantag strong reput around servic support
devic reliabl posit deliv beat rais quarter forese
quarter expect kick med-tech earn season like set investor
expect quarter relat procedur volum trend overal base
hospit administr survey may see normal strong season uptick investor
come expect still industri commentari sinc suggest dramat slowdown util trend
wed expect confirm specif expect see modest upsid estim
vs consensu believ consum continu turn around
pharma drive lion share out-performance continu adopt ramp like new
core drug includ tremfya darzalex well simponi stelara go-forward
basi expect manag bracket consensu sale ep guidanc organ sale
growth rang ep midpoint around think alreadi reflect
impact gener zytiga launch current sale growth project
ep estim anticip manag exercis normal prudent conservat particularli
gener zytiga realiti on-going nois around talc litig
stanc believ jnj diversifi busi model allow manag near-term
headwind specif one busi pharma patent cliff on-going turnaround
consum reacceler medic devic expect return market growth
above-market pharma growth profil believ well-posit ultim return sustain
above-market sale growth deliv even faster ep growth
recent note sell-off talc news overdon flash note
resultsactuallp estimate y/i growthconsensusvariancetot develop market administr incom ep domest domest direct sale compani report svb leerink estim resultsactuallp estimate y/i growthconsensusvariancenet gener administr develop ep region total product total medic devic consum compani report first order analyt consensu visibl alpha consensu svb leerink plc market perform price
quarter expect deliv sale ep basic in-lin estim
street recent manag commentari around
soft cvg cardiac vascular group now-low estim reflect organ sale
growth y/i vs manag guidanc quarter given growth
contribut new product launch includ integr insulin pump intelli
spinal cord stimul system fuel encourag sale out-performance
think growth momentum could continu help off-set weak
elsewher notabl lvad spine market continu under-perform
share donor deliv least small level margin
expans believ order drive stock out-performance overal variou put
take think difficult deliv meaning upsid particularli top-
line also expect manag rais sale ep guidanc
organ importantli investor like focu outlook
shape particularli manag highlight potenti below-trend ep growth due new
tax regul hope clariti around tax rate late februari
earn call potenti posit give color
stanc seem set deliv consist in-lin perform opportun
upsid next year remain sidelin pend clariti fundament
product launch on-going competit pressur spine despit
achiev long-term sale guidanc remain sidelin given believ modest
execut risk around new product launch posit leverag
quarter expect nvcn focu tiara clinic progress financi health
compani cash bank legal overhang remov still
compani cash posit like sustain develop less year point
manag hope posit reduc grow and/or partner tiara
much closer market nvcn report total number tiara implant reach
novemb vs august may march novemb believ
manag provid updat clinic trial progress tiara hope see acceler
enrol clariti potenti time tiara trial complet nvcn exit
cash hand suffici fund day-to-day oper next
month view
stanc view nvcn front-runn commerci tmvr transcatheth mitral
valv replac devic multi-billion market possibl peak much leerink
estim litig settl compani need provid anoth fundrais
plan remov financi overhang investor clariti nvcn continu
oper believ nvcn share move meaning higher appropri reflect
resultsactuallp estimate y/i growthtot good gross gener administr develop ep compani report svb leerink resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop ep region total product cardiac vascular group invas therapi group mitg therapi group compani report factset consensu visibl alpha consensu svb leerink corp outperform price
quarter expect pre-announce sale y/i
mid-point -- slightli ahead prior estim consensu
provid sale guidanc yet expect manag issu sale growth
guidanc midpoint vs us y/i vs midpoint prelim sale
consensu base preannounc thu far market grow
faster clip cite call like well mid-to-high
teen rang also appear perhap worst cede share seemingli
best held steadi vs isnt necessarili unexpect given compani well-
telegraph sale rep retent issu lack vice-president sale given compani alreadi
pre-announce think earn call focu go-to-market strategi potenti impact
versatil platform launch later time extent potenti revenu
contribut new indic statu sale forc ad net rep
note attrit come high-teen level though admittedli could
stanc confid nvro sustain double-digit sale growth trajectori given
broader spinal cord simul market project grow double-digit near-
term see increasingli favor risk/reward profil believ return share
gain posit improv execut back best-in-class clinic data even
quarter expect deliv top-lin beat rel consensu
driven strong adopt momentum compani continu roll dash system establish
market access pharmaci channel howev compani reiter guidanc conjunct
cfo departur announc last week seem unlik compani deliv
meaning upsid look expect guid acceler instal
base growth larg due rapidli expand market access manag expect
omnipod move pharmaci channel sale growth perspect believ
guid someth rang midpoint bracket estim y/i
consensu also expect manag provid color quarterli cadenc
move given new revenu model dash given away free
dash fulli launch late impact like pronounc wed
note manag overal believ revenu per patient per year remain unchang price
per pod move margin higher off-set
stanc view one cleanest execut stori within smid-cap coverag
univers compani pois continu deliv consist beat rais quarter top-
line sign slow momentum believ ramp adopt still larg under-penetrated
pump market primari market grower given highli differenti wearabl footprint
drive sustain double-digit growth forese futur addit
achiev sustain net incom profit
resultsactuallp estimate y/i growthconsensusvariancetot good gross gener administr develop ep metricsend us breakdowndomest compani report factset consensu visibl alpha consensu svb leerink resultsactuallp estimate y/i growthconsensusvariancetot good gross gener administr develop incom cont ep overviewtot us omnipod omnipod deliveri revenu compani report factset consensu first order analyt svb leerink hold inc outperform price
quarter expect come basic line estim factset
consensu driven primarili on-going eversens adopt momentum europ
potenti modest upsid launch key share perform view
anecdot commentari around on-going germani launch increment launch commentari
eu countri importantli launch eversens start juli
note eversens secur new patient add across rang patient type europ --
experienc libr user former user remain
type new cgm continu glucos monitor therapi strong adopt momentum
libr bode well eversens benefit libr expand market
captur exist libr patient prefer conveni long-wear sensor view
think increas focu adopt trend europ go
forward secur time dose claim next major catalyst stock near term
stanc believ verg dramat sale inflect point on-going
 launch eversens implant cgm continu glucos monitor
believ nearli total address market alon confid born
continu posit earli feedback on-going european launch expand
germani itali seem ramp well appear strong recept
patient physician could/should serv proxi ultim adopt
quarter expect deliv meaning upsid current estim
y/i street driven ramp maci adopt trend
compani continu train surgeon util new exist
center continu ramp despit face tough comp model current assum
exit train surgeon includ new surgeon train quarter
vs train util procedur per surgeon vs
estim us leav plenti room upsid manag
provid guidanc earn call believ like bracket
consensu y/i rang like consensu
estim given initi guid sale
y/i deliv first three quarter inclin think
conserv start year expect deliv gross margin
vs compani drive leverag ramp volum
stanc believ sustain top-lin grower next
year driven ramp adopt highli under-penetrated articular cartilag repair
market sever burn market peg combin maci epicel address market
opportun hold virtual monopoli maci actual
monopoli epicel addit believ gross margin continu improv
case volum continu ramp drive meaning oper leverag achiev ebit
net incom profit
resultsactuallp estimate y/i growthtot gross gener administr develop ep compani report svb leerink resultsactuallp estimate y/i growthconsensusvariancetot develop gener administr incom ep breakdowncarticel maci compani report factset consensu svb leerink healthcar
rate share outperform price target believ abiom
manufactur impella impella cp percutan ventricular assist devic
pvad well-posit deliv sustain strong double-digit sale growth near-
to-midterm time-frame project sale compound-annual-growth-rate
compani drive increas penetr prophylact high-risk percutan
coronari intervent pci cardiogen shock patient popul estim nearli
patient treat abiom impella impella cp
pci perform annual base medacorp physician
convers anywher pci could consid high-risk
would benefit impella anoth pci cardiogen shock patient
compani benefit new product higher flow impella cp receiv pma approv
 april indic shock new geographi notabl
japan receiv approv octob launch impella
addit receiv fda approv impella rp right heart failur
compani continu add new center
center total ad center per quarter
us biggest barrier impella adopt awar impella
pma-approv protect pci impella devic includ higher flow impella
cp approv cardiogen shock aggress market train
hospit heart team util broad clinic dataset train capabl impella
six clinic guidelin drive awar help guid clinic
practic eas patient select
even adopt inflect upon protect pci pma approv late believ
impella adopt pois ramp given
highli under-penetrated market opportun within protect pci cardiogen shock
impella today penetr
concert effort among physician rais awar around treat grow
number complex patient pci procedur volum patient grow
mid-single-digit rang base estim
pma approv protect pci cardiogen shock allow
aggress market impella use broad clinic dataset support safeti efficaci
cost-effect well train clinician nurs
indic geograph expans on-going launch impella rp
patient opportun on-going launch japan current
patient balloon pump patient extracorpor membran
oxygen ecmo repres low-hang fruit impella view
oper margin expans stori believ abiom drive on-going posit oper
leverag primarili within sg ultim push oper margin
next month believ share
move higher current level compani continu deliv consist quarterli sale
beat push oper margin higher
reiter op pt pt price target prior -- appli
ev/sal multipl estim assum stabl multipl vs current
estim continu believ top-tier sale growth profil
profit warrant premium repres uniqu asset increasingli volatil market
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
rate share market perform price target abbott
like path top-lin growth acceler compani like reinvest
busi absorb acquisit includ alr stj deal
potenti bolster compani sale ep growth outlook becom
formid player med-tech diagnost even broader offer
near term uncertainti around integr stj alr like continu
reflect market sentiment beyond believ margin expans continu
remain key piec abbott long-term invest thesi abbott also attract investor
look safer defens stock healthi dividend yield current
increasingli volatil market help sustain current multipl abbott
succeed drive meaning margin expans nutrit busi margin
mid-teen level post-split still go increas cost effici
suppli chain manufactur abbott pipelin also number smaller
increment new product launch expect next year beyond
pend acquisit xienc stori larg play estim basic
stabl drug elut stent market share next year view abbott like
less acquisit immedi term two larg acquisit underway alreadi
estim reflect uncertainti around integr larg acquisit stj
expect share trade assum multipl
ep estim basic line large-cap med-tech group
clearli pois sale growth acceler next year believ current
valuat alreadi reflect potenti execut risk around new product launch --
heavili depend notabl freestyl libr mri-saf high power devic --
see opportun potenti downsid vs meaning clear-cut upsid
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
rate share outperform price target
believ well-posit sustain double-digit top-lin growth least
next year compani core open ablat busi -- make
sale -- well-posit deliv sustain mid-single-digit growth forese futur
penetr ramp beyond guidelin chang acceler
continu advanc mi minim invas ablat pipelin could ultim
open multibillion-dollar atrial fibril af ablat market opportun address
atrial fibril patient
ceo carrel appear commit compani current long-term growth strategi
penetr concomit open heart surgic ablat market expand mi surgic
ablat drive atriclip sale cross-sel expand intern
near term manag work ensur limited-to-no sale forc disrupt compani
continu focu penetr leerink estim global concomit surgic
ablat market -- less penetr today compani success advanc
clinic trial initi converg frost deep progress
next month believ share trade valuat appli
ev/sal multipl revenu estim assum basic stabl multipl
current level estim compani get back track deliv
consist out-performance street estim move higher current level believ
share deserv least maintain slight discount broader small-cap med-tech
univers averag includ nxtm
believ compani continu deliv given stabl mid-to-high teen sale growth
outlook longer term mi come line potenti meaning sale oper
synergi estech ncontact acquisit close increasingli clear
pathway profit turn ebitda posit base estim
risk includ failur success execut surgeon train new af indic
adopt concomit surgic ablat clinic trial delay failur receiv
clearanc next gen atriclip system ou regulatori delay ncontact
rate share outperform price target ten consecut
beat rais ep quarter sinc spin oper margin alreadi track ahead
manag current long-rang plan increasingli strong free cash flow gener
believ post-spin new turnaround stori still room signific upsid
believ increment margin upsid potenti alreadi price believ magnitud
sale growth reacceler potenti free cash flow gener still underappreci
level increasingli becom strong free cash flow gener stori free
cash flow target vs potenti upsid free
cash flow view increas financi flexibl invest busi
drive even faster sale growth acceler invest inorgan outsid opportun
supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin
target believ margin expans stori alreadi least partli price
stock manag current guid oper margin
see room upsid margin ramp believ major
upsid alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement
price target arriv via ev/fcf ev/ ebitda analys estim
price-to-earnings perspect valuat impli multipl ep estim
repres modest multipl expans current level pe ep
line large-cap med-tech group support consist beat rais
quarter estim continu move higher
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
rate share outperform price target turnaround stori
well underway new manag deliv solid execut near- long-
term sale ep growth target build foundat sustain top-tier sale growth
within large-cap med-tech univers given compani recent consist deliv
ep line better expect upcom slew new product launch
increasingli confid well track achiev long-term goal laid
june analyst meet includ achiev organ sale growth
compound-annual-growth-rate -- faster broader med-tech market mid-single-digit rang
deliv gross margin achiev oper
margin togeth solidli posit deliv double-digit ep growth
next year view even growth guidanc slightli
organ sale growth deliv organ sale growth alreadi
well track view achiev long-term sale growth goal manag indic
confid sustain recent pipelin commerci execut
continu roll-out sever key new product launch meaning contributor
top bottom line includ limit watchman left atrial appendag
closur devic continu roll-out exceed expect mri-saf high
power devic launch symeti close pipelin
product coupl recent launch acquir product includ american medic
system am men prostat portfolio posit increment sale
growth acceler leav potenti upsid current project sale
litig overhang larg remov pois enter
stronger balanc sheet continu believ share well-posit
out-performance compani continu deliv consist quarter solid execut
next month believ share trade deriv appli
price-to-earnings multipl cash ep estim assum stabl multipl
price-to-earnings multipl ep slightli price-to-earnings large-cap med-tech group
broadli top-tier sale growth profil mid-to-
high singl digit rang healthier balanc sheet head think slight multipl
premium fair compani continu deliv solid execut consist meet-or-beat
quarter also ramp key new product move past litig issu see
opportun multipl expans ahead
risk includ lack meaning recoveri med-tech market broadli major boston
scientif market drug-elut stent de cardio rhythm monitor
specif failur success execut key new product launch major litig
loss potenti product recal particularli within inabl suffici reduc
cost drive oper margin expans
rate inc share outperform
month price target sever solid quarter row stabl improv growth
rel new ceo place believ compani reach fundament inflect point
sever quarter under-perform due sale forc disrupt poor execut
alway view well-posit market leader peripher atherectomi
market grow sustain high-single-digit rang coronari atherectomi market
grow even faster given competit advantag calcifi lesion knee
heavili under-penetrated market within space previou cautiou view
share larg predic lack execut august announc
interim ceo scott ward take perman continu transit make us
increasingli confid recent sale forc stabil thu improv growth trajectori
sustain near-to-medium term
longer term believ atherectomi market may posit acceler growth
advent drug coat balloon dcb particularli indic secur
knee within next year investor fear dcb competit
atherectomi devic medacorp physician check strongli suggest fact
complementari physician use atherectomi debulk prep lesion particularli
heavili calcifi sweet spot liberti still on-going
remain one compani develop substanti dataset support atherectomi
adopt highli under-penetrated market particularli sickest critic limb ischemia
patient larg untreat current lastli coronari gain like
continu aggress gain share also grow market believ reach
penetr total pci low-single-digit today
increas focu among intervent cardiologist treat complex higher risk patient
atherectomi like becom increasingli import
beyond top line csii effort control cost announc restructur march
includ reduct workforc could push compani profit faster
previous expect believ turn sustain net incom profit
current fiscal year pathway profit enabl attract broader
investor base attract new money name continu support share
price target previous -- appli ev/sal multipl
sale estim reflect basic stabl multipl vs
sale multipl sale estim smid-cap
coverag univers averag nxtm
reflect new product-rel execut risk
market share potenti product recal failur dcb drive atherectomi adopt
rate inc share outperform price target
longer term view continu glucos monitor cgm market opportun
compel potenti top estim target larg grow under-tr
patient popul type diabet initi ultim move much-larg type
patient popul seem particularli well-posit within market fda
industri work dilig toward ultim goal develop artifici pancrea
essenti cgm-augment insulin pump system automat accur dose
patient new patient adopt momentumand launchingi like
sustain sale growth near medium term despit competit headwind continu
product evolut includ possibl much less-costli type product conjunct
googl partnership help drive project sale compound-annual-growth-rate period
next month believ share could trade assum
share trade ev/sal estim share current trade
sale estim premium compar smid-cap med-tech
compani nxtm believ
continu deliv estim upsid sustain ev/sal multipl current level
ultim believ share warrant least modest premium smid-cap
med-tech stock univers given substanti highli under-penetrated total
address market per estim consist upsid potenti top-tier
risk includ failur continu evolv sensor technolog includ verili product
type patient toward sensor-integr pump potenti price pressur
increas competit potenti product recal reimburs issu
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul current intermedi risk potenti
low risk beyond might occur slower pace already-elev investor
expect continu believ intermedi risk indic repres massiv
increment market opportun estim intermedi risk doubl
address patient popul also believ ramp patient slower
saw inoper high risk given linger question around tavr durabl
longer term need seemingli intens market develop effort drive
referr particularli younger less sick portion intermedi risk patient popul
potenti increas surgeon pushback less sick patient popul
heart member ramp effort preserv surgic busi
ultim believ global tavr market exceed new indic come
on-line low risk eventu asymptomat ew guidanc given
view low risk ramp like slower seen high risk
intermedi risk patient popul near-to-medium term ew still beat
rais stori base earli read intermedi risk adopt ramp think beat
next month may smaller tougher come
last two year particularli light competit launch addit steadier intermedi
risk ramp vs step function chang growth street seem expect share current
trade earn becom increasingli difficult argu meaning
multipl expans
price target previous appli price-to-earnings multipl
ep estim pt assum multipl contract current
ep still large-cap group averag also think ew
market-lead posit highli under-penetrated total address market justifi
compani premium valuat rel rest large-cap med-tech group
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
rate share outperform op price target view
differenti technolog competitor larg under-penetr fast-grow long-
term oxygen therapi ltot market manufactur market portabl oxygen
concentr poc that gener view best-in-class base efficaci size allow
superior portabl patient mobil compani also implement uniqu direct-to-
consumer- dtc sale strategi despit well-known reimburs headwind protect
profit margin still allow higher invest versu competitor
time-frame project deliv sale compound-annual-growth-rate even
absorb increment reimburs cut
poc therapi class expand within ltot given favor demograph broaden
awar earlier diagnos underli condit copd longer life
expect oxygen therapi medacorp physician survey check suggest
poc could move much ltot mid-single-digit penetr today base
appropri patient
drive continu market share gain within poc increas awar
barrier adopt poc broadli compani inogen one specif exist
includ lack awar poc inogen one potenti higher
up-front cost patient versu tradit oxygen therapi awar continu grow
compani continu invest build sale forc dtc market effort
word mouth take hold cost frequent cite issu medacorp
physician survey spoken continu technolog improv higher
patient invest therapi decis could help mitig barrier us repres
compel invest opportun med-tech investor given high-sal growth
profit profil despit alreadi well-known reimburs headwind next
month believ share could move higher current level success execut
quarter potenti deliv upsid could prove conserv estim
price target vs prior appli ev/sal multipl
sale estim assum stabl multipl current
estim ev/sal multipl small-cap med-tech univers
broadli believ repres
uniqu asset within small-cap med-tech top-tier growth profil profit
risk share includ account issu possibl greater reimburs cut
current model loss increment competit bid contract exclud
compani access new patient potenti competitor replic implement
compani dtc strategi inabl build awar drive increas penetr
poc oxygen therapi market
rate share outperform price target johnson johnson
histor repres defens stock view johnson johnson seem also
becom offens compani success gener posit momentum
reacceler growth sinc suffer sever year below-industri growth
johnson johnson weather slow med-tech util trend ramp price pressur
major pharma patent expir actelion johnson johnson seem pois
drive sustain organ mid-single-digit top-lin growth even better high-single-digit bottom-
line growth long-term help success recent new pharma product launch zytiga
imbruvica xarelto invokana continu innovation/in-licens re-launch full
over-the-counter product portfolio basic stabl seemingli improv med-tech util
trend broadli depuy/synth trend specif compani work
integr issu dividend yield strong free cash flow gener believ
share repres attract total return vehicl investor
next month believ share trade price target price
target appli price-to-earnings multipl ep estim share current trade
ep estim large-cap med-tech group rang
price target assum see multipl
expans line broader comp group compani manag top-
line headwind continu manag cost benefit actelion --
posit sustain ep out-performance view total return capabl
attract increasingli volatil stock market environ like attract fund
risk includ failur success integr actelion amo synth potenti futur
acquisit failur resolv outstand consum consent decre success
re-launch product product recal failur advanc late-stag pipelin
success launch new product protract recoveri procedur volum trend
lack real macroeconom recoveri
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total
sale cardiac rhythm manag spine market estim grow
low-single-digit best mdt sustain growth trajectori larg predic
recent upcom new product launch well success integr covidien
largest acquisit compani histori
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans beyond cov synergi
major med-tech market broadli spine specif experienc real
share current trade ep assum stabl multipl
current multipl ep estim moder
area broader large-cap med-tech univers though believ
could eventu return path consist mid-single-digit top-lin growth time
less certain see limit multipl expans mid-single-
digit growth trajectori larg predic recent upcom new product launch
sustain trend without risk price target appli
basic stabl multipl ep estim
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
rate nvcn share outperform price target though still earli
develop believ neovasc verg tap dramat larg
potenti high growth transcathet mitral valv replac tmvr market tiara
technolog neovasc tiara current forefront still nascent develop
market total number implant reach patient either feasibl
compassion use mitral regurgit mr preval aortic stenosi
tmvr clearli repres massiv virtual unpenetr market opportun peg
global tmvr market opportun assum tmvr initi target function mr patient
high risk surgeri almost tripl current transcathet aortic valv
replac tavr market estim use tavr proxi clear demand
less invas transcathet therapi high valvular diseas patient mr particularli
sever mr repres highli underserv patient popul poor surgic outcom
drive surgic penetr rate less total market tiara clearli
without risk given earli stage develop medacorp physician check suggest
tiara repres highli viabl solut given anatom d-shape leaflet independ
next month believ nvcn share trade arriv price target
use discount cash flow dcf analysi take averag valuat base rang
royalti rate dcf use discount rate probability-
weight price target reflect averag believ possibl royalti rate
rang royalti pay-out conserv scenario view
acknowledg small-cap med-tech compani valu base compar compani
ev/sal multipl believ dcf best captur total address market opportun
neovasc tiara tmvr market estim potenti global
risk neovasc rate valuat includ possibl tiara and/or reduc
approv us and/or europ commerci ramp tiara and/or reduc fail
meet expect challeng fda approv pathway tiara and/or reduc
fairli robust competit landscap mr replac pipelin on-going trademark
potenti patent litig potenti reimburs risk failur obtain suffici
reimburs tiara and/or reduc secur approv
rate share outperform price target believ
midst dramat sale inflect point fda approv highli
differenti superior tradit therapi senza spinal cord
stimul system treat chronic pain current global market per
leerink estim also view differenti senza high frequenc therapi
like market growth stimul adopt predomin back pain patient larg
untreat previous due lack efficaci like acceler senza given
proven efficaci patient popul ultim see faster-grow
market increment market growth larg accru
believ deliv compound annual top-lin growth
see potenti upsid alreadi top-tier sale growth profil driven
rapid aggress market share gain back fda
approv senza hf -- label includ pivot trial data claim superior
dramat eu market share gain superior label place
senza-rct clinic data wide dispers public
peer-review medic journal releas data nan annual
meet decemb
potenti faster market growth aggress adopt therapi
increas sale forc ramp penetr key account beyond
next month believ share trade appli ev/
sale multipl sale estim assum stabl multipl vs current
estim discount small-cap med-tech coverag univers
ev/sal nxtm
risk share includ difficulti shift physician adopt away current
cut potenti high frequenc competit anoth major player could impact
long-term market share and/or forc enforc intellectu properti ip right
like time-consum expens effort increment reimburs cut may
pressur price longer term
rate share outperform price target next
year continu focu drive strong referr momentum increas sale
forc product greater awar deliv believ around
top-lin compound-annual-growth-rate time-frame ex neighborhood diabet underw
manag transit four year ago busi stabilized-to-acceler
believ long-term market opportun pump therapi unchang
penetr type patient today solid execut continu
reinvest sale forc appear pois drive sustain re-acceler
new patient add beyond diabet compani meaning opportun platform
drug deliveri technolog non-insulin sale underway expect ramp
least total sale next year base estim
continu rate share op pt appli ev/sal multipl
sale estim pt reflect upsid also take account multipl
re-rat broader smid-cap med-tech market share current trade
sale estim expect multipl hold current level given
believ sustain double-digit growth next year dramat
improv profit profil -- consist net incom posit believ share
deserv trade premium ev/sal multipl smid-cap med-tech
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
rate share outperform price target believ senseon
verg dramat sale inflect point european launch eversens
implant continu glucos monitor cgm progress even importantli
 launch believ nearli total address market alon
still today global cgm market still much earli stage adopt
increas awar improv reimburs continu technolog evolut
longer-wear implant sensor senseon eversens play key role
like continu drive rapid growth via expand patient popul eventu
aggress penetr beyond type much-larg multi-million type patient
popul view eversens appeal broad patient popul encompass
type current declin cgm option due high burden therapi
patient also type reason us posit compani dramat top-
line growth next year clear path profit
modest penetr type margin penetr insulin-depend
type believ senseon deliv compound-annual-growth-rate time-frame
ramp sale see potenti upsid
estim driven
solid launch execut supplement potenti faster sale forc add
success pipelin execut faster market entri sensor would
competit differenti gap
on-going launch eversens sensor beyond
continu roll-out eversens xl rest europ
beyond solid execut drive sale inflect expect benefit
number posit catalyst next month includ
secur dose claim eversens sensor
advanc clinic trial eversens xl
next month believ share trade appli ev/
sale multipl sale ev/sal sale
pt reflect confid potenti adopt trajectori given posit earli feedback
europ best-in-class mard ramp line better expect
share trade sale estim premium small-cap med-tech
coverag univers trade sale ultim believ premium warrant
risk share includ difficulti shift physician adopt away current
tradit cgm therapi increas competit counter-detail failur build
success sale forc train physician drive adopt failur advanc
pipelin includ sensor expand indic pediatr
rate share outperform price target believ
maintain virtual monopoli highli under-penetrated articular cartilag repair market
could ultim see open-end growth longer term recently-launch
maci product repair larg cartilag defect seen sale growth
acceler ytd mid-single-digit third-
gener product launch broadli one-of-it kind amount
support clinic data includ summit trial demonstr superior vs
standard care microfractur year carticel use first-gener product
maci procedur base eas use faster rehabilit
time increas appeal physician orthoped surgeon special
sport medicin patient physician train util maci continu
ramp believ deliv least maci sale growth next
three year mid-teen growth sustain go-forward basi high end
compar small-cap med-tech compani coverag univers
see signific opportun upsid alreadi above-street estim driven
even higher number orthoped surgeon util maci total
orthoped surgeon identifi sport medicin specialist model
current assum surgeon train exit
higher util new exist surgeon maci eas use benefit well
shorter rehabilit time could drive surgeon use even frequent
saw carticel current estim estim
assum maci procedur per surgeon project util drop
maci procedur per surgeon per quarter
favor gross margin profil variabl cog total
well-posit significantli expand gross margin ultim achiev
sustain oper incom net profit earlier beyond
also market autolog epiderm product address sever
burn market penetr believ epicel alon sustain high-single-
digit low-double-digit grower
next month believ share trade arriv valuat
use discount cash flow dcf compar compani ev/sal analysi dcf
arriv valuat compar compani analysi arriv
valuat rang valuat appli ev/sal multipl
sale estim current share trade
estim sale estim basic line view
compar higher-growth small-cap med-tech group sale estim
sale estim top-tier growth profil monopoli larg under-penetrated
market path profit believ share deserv trade least line
ev/sal multipl higher-growth smid-cap med-tech coverag univers
op rate
risk valuat includ inabl execut physician train drive ramp
maci adopt potenti product recalls/regulatori issu either maci epicel
competit entrant current unawar need rais addit capit
reach profit could dilut exist sharehold inabl optim
variabl cog control oper expens order drive posit leverag
dollar million except per share data
total good sold
research develop
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share amount
product sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share amount
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
product sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
total good sold
research develop expens
incom equiti invest
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
sale revenu
rental revenu
sold
research develop expens
 sale
 sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom attribut non-controlling
net incom attribut
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom continu oper
earn discontinu oper net tax
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
revenu report
oper revenu ex fx divestitur
compani report svb leerink estim
canadian dollar million except ep
good sold
loss foreign exchang
basic averag share million
good sold sale
sg sale ex med-tech tax
 sale
oper expens sale
good sold
basic dilut ep
compani report svb leerink estim
dollar million except per share data
total good sold
research develop
net incom compani
accret redeem convert prefer stock
cog sale
 sale
sg sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share data
good sold
accret redeem convert prefer stock
net loss attribut common stockhold
dilut averag share thousand
good sold sale
sg sale ex med-tech tax
devic tax sale
 sale
oper expens sale
good sold
net incom cont op
compani report svb leerink estim
dollar thousand except per share amount
sold
research develop expens
impair intang asset
increas decreas fair valu warrant
 sale
sg sale
oper expens sale
compani report svb leerink estim
